Relay Therapeutics, Inc.
RLAY · XNASCIK 1812364fmd_1WGK67PA9P38A0D8P1BHDTDH3AManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2019 to Sep 30, 2026, 31 periods
| Line item | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Total revenues | – | 83 | 3 | 1 | 26 | 10 | 15 |
| Research and development | 70 | 100 | 173 | 246 | 330 | 319 | 261 |
| Total operating expenses | 84 | 138 | 368 | 301 | 399 | 382 | 318 |
| Operating income | (84) | (56) | (365) | (299) | (373) | (372) | (303) |
| Other non-operating income (expense) | 9 | 3 | 1 | 9 | 31 | 35 | 26 |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | (75) | (230) | (364) | – | – | – | – |
| Net income | (75) | (52) | (364) | (291) | (342) | (338) | (276) |
| Net income to common shareholders | (75) | (230) | (364) | – | – | – | – |